International Journal of Probiotics and Dietetics(IJPD)

Endocrinology Division, Department of Medicine, Olive View, UCLA Medical Center, David-Geffen UCLA Medical School CA, USA

Publications

• Review Article   
  Efficacy and safety of Once-Weekly Insulin Icodec
  Author(s): Nasser Mikhail* and MD
  
  Insulin icodec is a long-acting once-weekly basal insulin analog that is currently under investigations. Efficacy and safety of insulin icodec were assessed in a series of 6 phase 3 clinical trials known as the ONWARDS Program; 5 trials in type 2 diabetes, and 1 trial in type 1 diabetes. In 4 of the 6 ONWARDS trials, reductions in glycated hemoglobin (HbA1c) levels were slightly greater with insulin icodec compared with once-daily insulin glargine or degludec with a mean difference of 0.19-0.38 percentage points. In the other 2 trials, insulin icodec was not inferior to insulin degludec in reducing HbA1c lev- els. Data analysis of continuous glucose monitoring (CGM) showed greater or similar time spent in range (TIR) with insulin icodec versus insulin glargine or degludec. In type 2 diabetes, patient satisfaction and compliance were superior with insulin icodec compared with insulin g.. Read More»
  

  Abstract HTML PDF